Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
31.73
-0.63 (-1.95%)
At close: Nov 7, 2025, 4:00 PM EST
32.00
+0.27 (0.85%)
After-hours: Nov 7, 2025, 4:47 PM EST
AAPG Revenue
Ascentage Pharma Group International had revenue of 233.70M CNY in the half year ending June 30, 2025, with 63.77% growth. This brings the company's revenue in the last twelve months to 390.60M, down -56.75% year-over-year. In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M with 341.77% growth.
Revenue (ttm)
390.60M CNY
Revenue Growth
-56.75%
P/S Ratio
54.07
Revenue / Employee
688,894 CNY
Employees
567
Market Cap
2.95B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AAPG News
- 5 days ago - Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 - GlobeNewsWire
- 5 days ago - Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 - GlobeNewsWire
- 10 days ago - Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - GlobeNewsWire
- 2 months ago - Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA - GlobeNewsWire
- 3 months ago - Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 - GlobeNewsWire
- 3 months ago - Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewsWire